Geneva, Switzerland – November 18, 2016 – Today, the Sabin Vaccine Institute (Sabin) begins its formal membership with the Coalition for Epidemic Preparedness Innovations (CEPI), as global health leaders gather in Geneva, Switzerland for the first meeting of CEPI’s Joint Coordination Group (JCG).
Vatican City – November 10, 2016 –Peter Hotez, M.D., Ph.D., president of the Sabin Vaccine Institute (Sabin) and director of the Sabin Product Development Partnership (Sabin PDP), today will help kick off the first-ever Vatican conference on neglected tropical diseases (NTDs) and rare diseases with a keynote address.
WASHINGTON, D.C. – October 17, 2016 – The Sabin Vaccine Institute joins a global community of friends, partners and global health advocates in celebrating the life of Heloisa Sabin (née Dunshee de Abranches), who passed away October 12 at the age of 98. Wife of the late Dr. Albert B. Sabin, who developed the oral live virus polio vaccine, Heloisa Sabin shared her late husband’s dedication to the elimination of needless human suffering and poverty.
Beijing, China — September 22, 2016 — The International Association of Immunization Managers (IAIM), based at the Sabin Vaccine Institute (Sabin), today began its first-ever regional meeting for members from Asia and the Pacific in Beijing, China.
Melbourne, Australia — September 7, 2016 — Beginning today, the 12th International Rotavirus Symposium will bring together hundreds of stakeholders from over 50 countries to provide an update on new data and research that will inform public health agendas related to prevention of rotavirus gastroenteritis, the leading cause of severe diarrhea in children worldwide.
Mexico City, Mexico – August 31, 2016 – Today, four leading institutions at the forefront of dengue prevention and control—the International Vaccine Institute (IVI), the International Vaccine Access Center (IVAC) of the Johns Hopkins University, the Partnership for Dengue Control Foundation (PDC) and the Sabin Vaccine Institute—announced a new global alliance to integrate approaches to fight dengue and other Aedes-transmitted diseases under one strategic umbrella. Named the Global Dengue and Aedes-transmitted Diseases Consortium (GDAC), this new partnership will expand its expertise in dengue to other Aedes-transmitted diseases including Zika, chikungunya and yellow fever, responding to the urgent need for coordination in the currently fragmented efforts to control the diseases transmitted by one of the world's most dangerous animals—the Aedes mosquito.
WASHINGTON, D.C. — August 25, 2016 — The Sabin Vaccine Institute announced today that it has received an award of US$468,328 from the U.S. Centers for Disease Control and Prevention (CDC) to support initiatives to improve sustainable immunization financing. The project, conducted in partnership with the Pan American Health Organization (PAHO), will support sustainable financing, planning and decision-making for immunization programs in low- and middle-income countries. The program will launch in the Democratic Republic of Congo, Senegal and Kenya in 2016.
KATHMANDU, NEPAL — July 19, 2016 — The Sabin Vaccine Institute’s Sustainable Immunization Financing (SIF) Program today assembled senior officials from 21 countries to share their successes in increasing government budget allocations for national immunization programs. Greater political commitment and advocacy are building the momentum needed for countries to fully finance their immunization programs by 2020 and achieve the goals set forth in the Global Vaccine Action Plan (GVAP).
WASHINGTON, D.C. — June 22, 2016 — The Sabin Vaccine Institute is partnering with King Saud University (KSU) in Riyadh, Saudi Arabia, to advance vaccine research and development capacity in the Middle East and North Africa. As part of the new $6.6 million agreement, Saudi scientists will receive technical training in vaccine development at the Sabin Vaccine Institute Product Development Partnership (Sabin PDP) laboratories in Houston, Texas.
Statement of Dr. Peter Hotez, President of the Sabin Vaccine Institute and Director of its Product Development Partnership on the Group of 7 (G7) Summit, at which the leaders of Japan, the United States, the United Kingdom, Germany, Canada, Italy and France affirmed a commitment to neglected tropical diseases (NTDs).